Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 7.57%.

  • Akebia Therapeutics' EBIT Margin rose 409800.0% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 2280900.0%. This contributed to the annual value of 31.51% for FY2024, which is 4310500.0% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' EBIT Margin is 7.57%, which was up 409800.0% from 22.55% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EBIT Margin ranged from a high of 26.97% in Q2 2022 and a low of 149.95% during Q2 2021
  • Moreover, its 5-year median value for EBIT Margin was 31.0% (2023), whereas its average is 48.28%.
  • Data for Akebia Therapeutics' EBIT Margin shows a peak YoY increase of 2747300bps (in 2021) and a maximum YoY decrease of -573300bps (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Akebia Therapeutics' EBIT Margin stood at 113.28% in 2021, then soared by 92bps to 8.73% in 2022, then soared by 88bps to 1.07% in 2023, then plummeted by -2776bps to 30.77% in 2024, then soared by 125bps to 7.57% in 2025.
  • Its EBIT Margin was 7.57% in Q3 2025, compared to 22.55% in Q2 2025 and 23.57% in Q1 2025.